Dianthus Therapeutics (DNTH) CEO sells 166,000 shares after option exercise
Rhea-AI Filing Summary
Dianthus Therapeutics CEO and President Garcia Marino reported multiple insider trades dated August 7, 2026. He exercised stock options to acquire 166,000 shares of common stock at an exercise price of $8.44 per share, then on the same date sold 166,000 common shares in a series of open‑market or private transactions at weighted average prices such as $107.49, $108.05 and $110.76 per share. Footnotes state that the reported transaction was effected under a Rule 10b5‑1 trading plan adopted on May 8, 2026, and that the options, expiring June 6, 2032, began vesting on November 1, 2022 with the remainder vesting in equal monthly installments over three years, subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 166,000 shares ($16.54M approx. pre-tax spread)
Exercise and Sale
11 txns
Insider
Garcia Marino
Role
CEO AND PRESIDENT
Sold
166,000 shs ($17.95M)
Approx. gross sale proceeds
$17.95M
Approx. exercise cost
$1.40M
Approx. pre-tax spread
$16.54M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F8 | 40,000 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F8 | 126,000 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 40,000 | $8.44 | $338K |
| Exercise | Common Stock | 126,000 | $8.44 | $1.06M |
| Sale | Common Stock F1, F2 | 10,384 | $107.49 | $1.12M |
| Sale | Common Stock F1, F3 | 23,907 | $108.05 | $2.58M |
| Sale | Common Stock F1, F4 | 2,373 | $109.10 | $259K |
| Sale | Common Stock F1, F5 | 2,536 | $110.02 | $279K |
| Sale | Common Stock F1 | 800 | $110.76 | $89K |
| Sale | Common Stock F6 | 104,091 | $107.96 | $11.24M |
| Sale | Common Stock F7 | 21,909 | $108.72 | $2.38M |
Holdings After Transaction:
Stock Option (Right to Buy) — 160,004 shares (Direct);
Common Stock — 65,292 shares (Direct)
Footnotes (8)
- F1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2026.
- F2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $106.68 to $107.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.68 to $108.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $108.74 to $109.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $109.75 to $110.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.52 to $108.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- F7. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $108.57 to $108.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F8. The shares of common stock underlying this stock option award vested as to 25% of the shares on November 1, 2022, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Key Figures
Options exercised: 166,000 shares
Option exercise price: $8.44 per share
Common shares sold: 166,000 shares
+3 more
6 metrics
Options exercised
166,000 shares
Total shares underlying stock options exercised into common stock on August 7, 2026
Option exercise price
$8.44 per share
Exercise price for stock options expiring on June 6, 2032
Common shares sold
166,000 shares
Total Dianthus Therapeutics common shares sold in non-derivative transactions on August 7, 2026
Sale block price
$107.96 per share
Weighted average price for 104,091 common shares sold on August 7, 2026
Sale block price
$108.72 per share
Weighted average price for 21,909 common shares sold on August 7, 2026
Rule 10b5-1 plan date
May 8, 2026
Adoption date of Garcia Marino’s Rule 10b5-1 trading plan referenced in the footnotes
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy)
3 terms
Rule 10b5-1 trading plan financial
"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported above is a weighted average price. The shares were sold in multiple transactions..."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"The security title is Stock Option (Right to Buy) for the derivative transactions reported by Garcia Marino."
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did Dianthus Therapeutics (DNTH) CEO Garcia Marino report on August 7, 2026?
Garcia Marino exercised stock options covering 166,000 shares at $8.44 per share and sold 166,000 common shares in multiple open‑market or private trades that day. The sales were executed in several blocks at weighted average prices around $108 per share.
How many Dianthus Therapeutics (DNTH) stock options did Garcia Marino exercise and at what price?
He exercised stock options for 166,000 shares of Dianthus Therapeutics common stock at an exercise price of $8.44 per share. According to the disclosure, these options are scheduled to expire on June 6, 2032, following a vesting schedule that began in November 2022.
Were Garcia Marino’s Dianthus Therapeutics (DNTH) trades made under a Rule 10b5-1 trading plan?
Yes. A footnote specifies that the reported transaction was effected pursuant to a Rule 10b5‑1 trading plan adopted by Garcia Marino on May 8, 2026. The filing also marks the Rule 10b5‑1 affirmation checkbox as true for these reported transactions.